Effect of amantadine in essential tremor: a randomized, placebo-controlled trial.
Identifieur interne : 001503 ( Ncbi/Checkpoint ); précédent : 001502; suivant : 001504Effect of amantadine in essential tremor: a randomized, placebo-controlled trial.
Auteurs : Alexandre Gironell [Espagne] ; Jaime Kulisevsky ; Berta Pascual-Sedano ; David FlamarichSource :
- Movement disorders : official journal of the Movement Disorder Society [ 0885-3185 ] ; 2006.
English descriptors
- KwdEn :
- MESH :
- chemical , therapeutic use : Amantadine, Antiparkinson Agents.
- drug effects : Motor Activity.
- drug therapy : Essential Tremor.
- Aged, Cross-Over Studies, Disability Evaluation, Double-Blind Method, Female, Humans, Male, Middle Aged, Neurophysiology, Treatment Outcome.
Abstract
There is a need for new medication for essential tremor (ET). Preliminary evidence suggests that amantadine may be effective in the treatment of ET. We studied the effects of amantadine in a double-blind, cross-over, placebo-controlled trial in ET patients. Sixteen patients with ET received amantadine 100 mg b.i.d. and placebo for 15 days, with a 1-week wash-out period between treatments. Major evaluation outcomes consisted of a tremor clinical rating scale, accelerometric recordings, and a self-reported disability scale obtained before drug intake and on study days 1 and 15 of each treatment period. A two-way repeated measures analysis of variance (treatment, time) was applied. Any P value < 0.05 was considered significant. On day 15, amantadine did not demonstrate any significant efficacy in reducing tremor with respect to baseline in any tremor measures. An increase in postural tremor as an adverse effect of amantadine was referred by 37.5% of patients. Results from the present trial indicate amantadine at 100 mg b.i.d. is not effective as a treatment for ET.
DOI: 10.1002/mds.20676
PubMed: 16229019
Affiliations:
Links toward previous steps (curation, corpus...)
- to stream PubMed, to step Corpus: 002E26
- to stream PubMed, to step Curation: 002E26
- to stream PubMed, to step Checkpoint: 002D57
- to stream Ncbi, to step Merge: 001503
- to stream Ncbi, to step Curation: 001503
Links to Exploration step
pubmed:16229019Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Effect of amantadine in essential tremor: a randomized, placebo-controlled trial.</title>
<author><name sortKey="Gironell, Alexandre" sort="Gironell, Alexandre" uniqKey="Gironell A" first="Alexandre" last="Gironell">Alexandre Gironell</name>
<affiliation wicri:level="1"><nlm:affiliation>Movement Disorders Unit, Department of Neurology, Sant Pau Hospital, Autonomous University of Barcelona, Catalonia, Spain.</nlm:affiliation>
<country xml:lang="fr">Espagne</country>
<wicri:regionArea>Movement Disorders Unit, Department of Neurology, Sant Pau Hospital, Autonomous University of Barcelona, Catalonia</wicri:regionArea>
<wicri:noRegion>Catalonia</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Kulisevsky, Jaime" sort="Kulisevsky, Jaime" uniqKey="Kulisevsky J" first="Jaime" last="Kulisevsky">Jaime Kulisevsky</name>
</author>
<author><name sortKey="Pascual Sedano, Berta" sort="Pascual Sedano, Berta" uniqKey="Pascual Sedano B" first="Berta" last="Pascual-Sedano">Berta Pascual-Sedano</name>
</author>
<author><name sortKey="Flamarich, David" sort="Flamarich, David" uniqKey="Flamarich D" first="David" last="Flamarich">David Flamarich</name>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">PubMed</idno>
<date when="2006">2006</date>
<idno type="doi">10.1002/mds.20676</idno>
<idno type="RBID">pubmed:16229019</idno>
<idno type="pmid">16229019</idno>
<idno type="wicri:Area/PubMed/Corpus">002E26</idno>
<idno type="wicri:Area/PubMed/Curation">002E26</idno>
<idno type="wicri:Area/PubMed/Checkpoint">002D57</idno>
<idno type="wicri:Area/Ncbi/Merge">001503</idno>
<idno type="wicri:Area/Ncbi/Curation">001503</idno>
<idno type="wicri:Area/Ncbi/Checkpoint">001503</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en">Effect of amantadine in essential tremor: a randomized, placebo-controlled trial.</title>
<author><name sortKey="Gironell, Alexandre" sort="Gironell, Alexandre" uniqKey="Gironell A" first="Alexandre" last="Gironell">Alexandre Gironell</name>
<affiliation wicri:level="1"><nlm:affiliation>Movement Disorders Unit, Department of Neurology, Sant Pau Hospital, Autonomous University of Barcelona, Catalonia, Spain.</nlm:affiliation>
<country xml:lang="fr">Espagne</country>
<wicri:regionArea>Movement Disorders Unit, Department of Neurology, Sant Pau Hospital, Autonomous University of Barcelona, Catalonia</wicri:regionArea>
<wicri:noRegion>Catalonia</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Kulisevsky, Jaime" sort="Kulisevsky, Jaime" uniqKey="Kulisevsky J" first="Jaime" last="Kulisevsky">Jaime Kulisevsky</name>
</author>
<author><name sortKey="Pascual Sedano, Berta" sort="Pascual Sedano, Berta" uniqKey="Pascual Sedano B" first="Berta" last="Pascual-Sedano">Berta Pascual-Sedano</name>
</author>
<author><name sortKey="Flamarich, David" sort="Flamarich, David" uniqKey="Flamarich D" first="David" last="Flamarich">David Flamarich</name>
</author>
</analytic>
<series><title level="j">Movement disorders : official journal of the Movement Disorder Society</title>
<idno type="ISSN">0885-3185</idno>
<imprint><date when="2006" type="published">2006</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Aged</term>
<term>Amantadine (therapeutic use)</term>
<term>Antiparkinson Agents (therapeutic use)</term>
<term>Cross-Over Studies</term>
<term>Disability Evaluation</term>
<term>Double-Blind Method</term>
<term>Essential Tremor (drug therapy)</term>
<term>Female</term>
<term>Humans</term>
<term>Male</term>
<term>Middle Aged</term>
<term>Motor Activity (drug effects)</term>
<term>Neurophysiology</term>
<term>Treatment Outcome</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Amantadine</term>
<term>Antiparkinson Agents</term>
</keywords>
<keywords scheme="MESH" qualifier="drug effects" xml:lang="en"><term>Motor Activity</term>
</keywords>
<keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Essential Tremor</term>
</keywords>
<keywords scheme="MESH" xml:lang="en"><term>Aged</term>
<term>Cross-Over Studies</term>
<term>Disability Evaluation</term>
<term>Double-Blind Method</term>
<term>Female</term>
<term>Humans</term>
<term>Male</term>
<term>Middle Aged</term>
<term>Neurophysiology</term>
<term>Treatment Outcome</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">There is a need for new medication for essential tremor (ET). Preliminary evidence suggests that amantadine may be effective in the treatment of ET. We studied the effects of amantadine in a double-blind, cross-over, placebo-controlled trial in ET patients. Sixteen patients with ET received amantadine 100 mg b.i.d. and placebo for 15 days, with a 1-week wash-out period between treatments. Major evaluation outcomes consisted of a tremor clinical rating scale, accelerometric recordings, and a self-reported disability scale obtained before drug intake and on study days 1 and 15 of each treatment period. A two-way repeated measures analysis of variance (treatment, time) was applied. Any P value < 0.05 was considered significant. On day 15, amantadine did not demonstrate any significant efficacy in reducing tremor with respect to baseline in any tremor measures. An increase in postural tremor as an adverse effect of amantadine was referred by 37.5% of patients. Results from the present trial indicate amantadine at 100 mg b.i.d. is not effective as a treatment for ET.</div>
</front>
</TEI>
<affiliations><list><country><li>Espagne</li>
</country>
</list>
<tree><noCountry><name sortKey="Flamarich, David" sort="Flamarich, David" uniqKey="Flamarich D" first="David" last="Flamarich">David Flamarich</name>
<name sortKey="Kulisevsky, Jaime" sort="Kulisevsky, Jaime" uniqKey="Kulisevsky J" first="Jaime" last="Kulisevsky">Jaime Kulisevsky</name>
<name sortKey="Pascual Sedano, Berta" sort="Pascual Sedano, Berta" uniqKey="Pascual Sedano B" first="Berta" last="Pascual-Sedano">Berta Pascual-Sedano</name>
</noCountry>
<country name="Espagne"><noRegion><name sortKey="Gironell, Alexandre" sort="Gironell, Alexandre" uniqKey="Gironell A" first="Alexandre" last="Gironell">Alexandre Gironell</name>
</noRegion>
</country>
</tree>
</affiliations>
</record>
Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/MovDisordV3/Data/Ncbi/Checkpoint
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001503 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Ncbi/Checkpoint/biblio.hfd -nk 001503 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien |wiki= Wicri/Santé |area= MovDisordV3 |flux= Ncbi |étape= Checkpoint |type= RBID |clé= pubmed:16229019 |texte= Effect of amantadine in essential tremor: a randomized, placebo-controlled trial. }}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Ncbi/Checkpoint/RBID.i -Sk "pubmed:16229019" \ | HfdSelect -Kh $EXPLOR_AREA/Data/Ncbi/Checkpoint/biblio.hfd \ | NlmPubMed2Wicri -a MovDisordV3
This area was generated with Dilib version V0.6.23. |